Aurobindo Pharma Ltd has received final approval from the US Food and Drug Administration to manufacture and market Lamivudine and Zidovudine tablets.
The tablets are the generic equivalent of ViiV Healthcare Company’s Combivir tablets and are indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults and children.
The product, which was approved out of Unit VII formulations facility of the company here, was ready for launch, Aurobindo Pharma said in a release on Thursday.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.